Design and Development of a Novel Orally-Active, PI3K-p110Beta/Delta Inhibitor with Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity

被引：2

作者：

Shuttleworth, Stephen Joseph ^{[1
]}

机构：

[1] Karus Therapeut, Abingdon, Oxon, England

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.2052.2052

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 7 条

[1] Design and development of a novel series of PI3K-p110beta/delta-selective inhibitors with combined tumor immunotherapeutic, growth inhibition, and anti-metastatic activity
Shuttleworth, Stephen J.
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
[2] Design and development of a novel series of orally active, selective PI3K-p110β/δ inhibitors for the treatment of solid and hematological cancers
Shuttleworth, Stephen J.
CANCER RESEARCH, 2015, 75
[3] Anti-tumor activity of CAL-101, a potent selective inhibitor of the p110Δ isoform of PI3K, in models of human glioblastoma
Kashishian, Adam
Meadows, Sarah
Steiner, Bart
Lannutti, Brian
CANCER RESEARCH, 2011, 71
[4] CX-4945, an Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Exhibits Synergy When Combined with the PI3K-Δ Inhibitor GS-1101 or Fludarabine
Prins, Renee C.
Burke, Russell T.
Loriaux, Marc M.
Druker, Brian J.
Spurgeon, Stephen E.
BLOOD, 2012, 120 (21)
[5] A novel anti-angiogenic/anti-metastatic peptide, ATN-161 (Ac-PHSCN-NH2), which targets multiple fully activated integrins including alpha-5 beta-1 and alpha-v beta-3, leads to increased anti-tumor activity and increased survival in multiple tumor models when combined with chemotherapy
Plunkett, ML
Tel-Tsur, Z
Bera, M
Beck, I
Avery, J
Livant, DL
Mazar, AP
EUROPEAN JOURNAL OF CANCER, 2002, 38 : S79 - S79
[6] P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) shows anti-tumor activity in triple negative breast cancer
Agarwal, Veena R.
Bhatia, Dimple
Joshi, Asavari
Mishra, Prabha
Bharadwaj, Kalyani G.
Lobo, Aurelio S.
Menon, Pranoy
Dhar, Payal
Pandey, Prashant
Srinivasa, Sreesha
Sonawane, Vinay
CANCER RESEARCH, 2014, 74 (19)
[7] The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition
Mologni, Luca
Magistroni, Vera
Casuscelli, Francesco
Montemartini, Marisa
Gambacorti-Passerini, Carlo
JOURNAL OF CANCER, 2017, 8 (01): : 140 - 145

← 1 →